Cassava is available year round. It’s quite hard to peel, so it’s easiest to buy it ready prepared and frozen. If you do see it fresh, look for a clear outer skin and white flesh. Cassava ...

The Earth's plates jostle about in fits and starts that are punctuated with earthquakes and volcanic eruptions. 4 min read There are a few handfuls of major plates and dozens of smaller ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

However, fourth place is held by a dark horse: cassava. While nearly unknown in temperate climates, cassava is a key source ...

Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...